[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652599":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":38,"locations":44,"responsibleParty":115,"collaborators":117,"id":124,"slug":125,"hasResults":126,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":10,"eligibilityCriteria":130,"healthyVolunteers":126,"sex":131,"minAge":132,"maxAge":10,"enrollmentInfo":133,"targetDuration":10,"studyType":136,"phases":10,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"PD-L1 Inhibitor Rechallenge Cohort",null,"Participants with lung cancer who developed checkpoint inhibitor pneumonitis and subsequently restarted immune checkpoint inhibitor therapy with a PD-L1 inhibitor after interruption of immunotherapy because of pneumonitis. Rechallenge treatment is selected by the treating physician as part of routine clinical care and is not assigned by the study protocol.",[13],"Drug: PD-L1 Inhibitor Rechallenge",{"label":15,"type":10,"description":16,"interventionNames":17},"PD-1 Inhibitor Rechallenge Cohort","Participants with lung cancer who developed checkpoint inhibitor pneumonitis and subsequently restarted immune checkpoint inhibitor therapy with a PD-1 inhibitor after interruption of immunotherapy because of pneumonitis. Rechallenge treatment is selected by the treating physician as part of routine clinical care and is not assigned by the study protocol.",[18],"Drug: PD-1 Inhibitor Rechallenge",{"label":20,"type":10,"description":21,"interventionNames":22},"No Immune Checkpoint Inhibitor Rechallenge Cohort","Participants with lung cancer who developed checkpoint inhibitor pneumonitis and did not restart PD-1 or PD-L1 inhibitor therapy. Subsequent antitumor treatment, if any, is selected by the treating physician according to routine clinical practice.",[23],"Drug: No Immune Checkpoint Inhibitor Rechallenge",[25,30,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DRUG","PD-L1 Inhibitor Rechallenge","Restarting immune checkpoint inhibitor treatment with a PD-L1 inhibitor after checkpoint inhibitor pneumonitis has improved and immunotherapy has been interrupted because of pneumonitis. The treatment is selected by the treating physician and is not assigned by the study protocol.",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"PD-1 Inhibitor Rechallenge","Restarting immune checkpoint inhibitor treatment with a PD-1 inhibitor after checkpoint inhibitor pneumonitis has improved and immunotherapy has been interrupted because of pneumonitis. The treatment is selected by the treating physician and is not assigned by the study protocol.",[15],{"type":26,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"No Immune Checkpoint Inhibitor Rechallenge","Participants do not restart PD-1 or PD-L1 inhibitor therapy after checkpoint inhibitor pneumonitis. Subsequent antitumor management follows routine clinical practice.",[20],[39],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Laiyu Liu","CONTACT","+86 13632102245","liulaiyu@sina.com",[45,64,71,85,100],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510030","China","CN",{"type":54,"coordinates":55},"Point",[56,57],113.25,23.11667,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":62,"phoneExt":10,"email":63},"Cchengzhi Zhou","+86 18028045334","doctorzcz@163.com",{"facility":5,"status":47,"city":48,"state":49,"zip":65,"country":51,"countryCode":52,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"510400",{"type":54,"coordinates":67},[56,57],{"lat":57,"lon":56},[70],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},{"facility":72,"status":47,"city":73,"state":49,"zip":74,"country":51,"countryCode":52,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Shenzhen People's Hospital","Shenzhen","518020",{"type":54,"coordinates":76},[77,78],114.0683,22.54554,{"lat":78,"lon":77},[81],{"name":82,"role":41,"phone":83,"phoneExt":10,"email":84},"Di Wu","+86 136 6258 9160","wudi315817@163.com",{"facility":86,"status":47,"city":87,"state":88,"zip":89,"country":51,"countryCode":52,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"The Second Affiliated Hospital of Nanchang University","Nanchang","Jiangxi","330200",{"type":54,"coordinates":91},[92,93],115.85306,28.68396,{"lat":93,"lon":92},[96],{"name":97,"role":41,"phone":98,"phoneExt":10,"email":99},"Xinyi Zhang","+86 791 8631 1242","zhangxinyi80@163.com",{"facility":101,"status":47,"city":102,"state":103,"zip":104,"country":51,"countryCode":52,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang","325088",{"type":54,"coordinates":106},[107,108],120.66682,27.99942,{"lat":108,"lon":107},[111],{"name":112,"role":41,"phone":113,"phoneExt":10,"email":114},"Xiaoying Huang","+86 577 55579272","zjwzhxy@126.com",{"type":116,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[118,119,121,122],{"name":46,"class":6},{"name":120,"class":6},"Second Affiliated Hospital of Nanchang University",{"name":72,"class":6},{"name":123,"class":6},"First Affiliated Hospital of Wenzhou Medical University","100652599","pd-l1-inhibitor-rechallenge-after-immunotherapy-related-pneumonitis-in-patients-with-lung-cancer-100652599",false,"NCT07775820","PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer","Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Histologically confirmed lung cancer.\n3. Development of checkpoint inhibitor pneumonitis after treatment with immune checkpoint inhibitor.\n4. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Incomplete clinical information required for the study analyses.\n2. Considered unsuitable for participation by the investigator.","ALL","18 Years",{"count":134,"type":135},150,"ESTIMATED","OBSERVATIONAL","This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.\n\nThe study will use both retrospective medical records and prospective follow-up data. Participants will not be assigned to any treatment by the study protocol. All treatment decisions will be made by the treating physicians as part of routine clinical care.\n\nParticipants will be classified into three groups according to their subsequent treatment: rechallenge with a PD-L1 inhibitor, rechallenge with a PD-1 inhibitor, or no immune checkpoint inhibitor rechallenge. The primary outcome is the recurrence of checkpoint inhibitor pneumonitis after rechallenge. Secondary outcomes include immune-related adverse events, progression-free survival, overall survival, objective response rate, and disease control rate at 24 weeks.\n\nApproximately 150 participants will be included across multiple study centers in China.",[139,140,141],"Lung Cancer","Rechallenge","Checkpoint Inhibitor Pneumonitis",[143,144,145,146,141,147,148],"Immune Checkpoint Inhibitor","PD-L1 Inhibitor","PD-1 Inhibitor","Immune Checkpoint Inhibitor Rechallenge","Immune-Related Adverse Events","Real-World Study","2026-08-18",{"date":151,"type":152},"2026-08-20","ACTUAL",{"date":154,"type":152},"2025-10-20",{"date":156,"type":135},"2027-06-30",{"name":5,"class":6},5]